GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
To evaluate safety and response rate of durvalumab/tremelimumab in combination with
paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Hallym University Medical Center Seoul National University Bundang Hospital